Shopping Cart 0
Cart Subtotal
USD 0

Antifibrinolytic Drugs Market by Indication (Gynecology, Hereditary Angiedema, Fibrinolytic Response Testing, Surgeries, and Others) and End user (Hospitals & Clinics, Ambulatory Surgical Centers, and Healthcare Specialty Process): Global Opportunity Analysis and Industry Forecast, 2019-2026

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 5370

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 8995

Details

The global antifibrinolytic drugs market was valued at USD 1,3593 million in 2018 and is expected to reach USD 1,9333 million by 2026, registering a CAGR of 4.5% from 2019 to 2026. Antifibrinolytic is a type of drug that helps in the formation of blood clot. These drugs prevent the breakdown of fibrin, which is the main protein involved in blood clotting. These drugs can be used to prevent serious bleeding in patients suffering from life threatening conditions such as hemophilia, very heavy menstrual bleeding, or some types of vascular tumors. They are also widely used to prevent or control bleeding during or after surgery or after a traumatic injury. An increase in usage of these drugs has been witnessed since past few years, owing to their increased applications.
 
Rise in medical surgeries including dental and cardiac, accidental trauma, and increase in incidence of angioedema across the globe are the major factors that drive the antifibrinolytic drugs market growth. Antifibrinolytic drugs play a crucial role in the prevention of clot lysis and blood loss. Considerable surge in prevalence of bleeding disorders propels the antifibrinolytic drugs market growth. However, high cost of these drugs hamper the market growth. Furthermore, increase in research & development for developing novel innovative antifibrinolytic drugs is anticipated to create new opportunities for the market.
 
The market is segmented on the basis of indication, end-users, and region. On the basis of indication, it is classified into gynecology, hereditary angiedema, fibrinolytic response testing, surgeries, and others. By end user, it is divided into hospitals & clinics, ambulatory surgical centers, and healthcare specialty process. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
 
KEY BENEFITS FOR STAKEHOLDERS
 
The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
It offers a quantitative analysis from 2018 to 2026, which is expected to enable the stakeholders to capitalize on prevailing market opportunities.
Comprehensive analysis of all geographical regions is provided to determine the prevailing opportunities.
Key players are profiled, and their strategies are analyzed thoroughly to understand the competitive outlook of the global market.
 
KEY MARKET SEGMENTS
By Indication
Gynecology
Hereditary Angiedema
Fibrinolytic Response Testing
Surgeries
Others
By End User
Hospitals & Clinics
Ambulatory Surgical Centers
Trauma Centers
By Region
North America
o U.S.
o Canada
o Mexico
Europe
o Germany
o France
o UK
o Italy
o Rest of Europe
Asia Pacific
o Japan
o China
o India
o Rest of Asia-Pacific
LAMEA
o Brazil
o Saudi Arabia
o South Africa
o Rest of LAMEA
 
KEY PLAYERS
 
Acic Fine Chems
Xanodyne Pharmaceuticals
Aurobindo Pharma Ltd
Akorn
Mylan N.V.
Pfizer (GenMed)
Sanofi SA
Zydus Cadila
Takeda
Amerigen Pharms Ltd
 
READ MORE

Table Of Content

Scope

Chapter 1: Introduction

 

1.1. Report Description

1.2. Key Benefits For Stakeholders

1.3. Key Market Segments

1.4. Research Methodology

 

1.4.1. Secondary Research

1.4.2. Primary Research

1.4.3. Analyst Tools And Models

 

Chapter 2: Executive Summary

 

2.1. Key Findings of The Study

2.2. Cxo Perspective

 

Chapter 3: Market Overview

 

3.1. Market Definition And Scope

3.2. Key Findings

 

3.2.1. Top Investment Pockets

 

3.3. Porter'S Five Forces Analysis

 

3.3.1. Moderate Bargaining Power of Buyers

3.3.2. Low Bargaining Power of Suppliers

3.3.3. Moderate Threat of Substitutes

3.3.4. Low Threat of New Entrants

3.3.5. Moderate Competitive Rivalry

 

3.4. Top Player Positioning

3.5. Market Dynamics

 

3.5.1. Drivers

 

3.5.1.1. Surge In Severe Road Accidents

3.5.1.2. Significant Increase In Surgical Procedures

 

3.5.2. Restraint

 

3.5.2.1. High Cost of These Drugs

 

3.5.3. Opportunity

 

3.5.3.1. Various Growth Opportunities In Emerging Economies

 

Chapter 4: Antifibrinolytic Drugs Market, By Indication

 

4.1. Overview

 

4.1.1. Market Size And Forecast

 

4.2. Gynecology

 

4.2.1. Key Market Trends And Opportunities

4.2.2. Market Size And Forecast

4.2.3. Market Share Analysis, By Country

 

4.3. Hereditary Angioedema

 

4.3.1. Key Market Trends And Growth Opportunities

4.3.2. Market Size And Forecast

4.3.3. Market Share Analysis, By Country

 

4.4. Fibrinolytic Response Testing

 

4.4.1. Key Market Trends And Opportunities

4.4.2. Market Size And Forecast

4.4.3. Market Share Analysis, By Country

 

4.5. Surgeries

 

4.5.1. Key Market Trends And Opportunities

4.5.2. Market Size And Forecast

4.5.3. Market Share Analysis, By Country

 

4.6. Others

 

4.6.1. Key Market Trends And Opportunities

4.6.2. Market Size And Forecast

4.6.3. Market Share Analysis, By Country

 

Chapter 5: Antifibrinolytic Drugs Market, By End User

 

5.1. Overview

 

5.1.1. Market Size And Forecast

 

5.2. Hospitals

 

5.2.1. Market Size And Forecast

5.2.2. Market Share Analysis, By Country

 

5.3. Ambulatory Surgery Centers

 

5.3.1. Market Size And Forecast

5.3.2. Market Share Analysis, By Country

 

5.4. Trauma Centers

 

5.4.1. Market Size And Forecast

5.4.2. Market Share Analysis, By Country

 

Chapter 6: Antifibrinolytic Drugs Market, By Region

 

6.1. Overview

 

6.1.1. Market Size And Forecast

 

6.2. North America

 

6.2.1. Key Market Trends And Opportunities

6.2.2. Market Size And Forecast, By Country

6.2.3. Market Size And Forecast, By Indication

6.2.4. Market Size And Forecast, By End User

6.2.5. U.S.

 

6.2.5.1. U.S. Market Size And Forecast, By Indication

6.2.5.2. U.S. Market Size And Forecast, By End User

 

6.2.6. Canada

 

6.2.6.1. Canada Market Size And Forecast, By Indication

6.2.6.2. Canada Market Size And Forecast, By End User

 

6.2.7. Mexico

 

6.2.7.1. Mexico Market Size And Forecast, By Indication

6.2.7.2. Mexico Market Size And Forecast, By End User

 

6.3. Europe

 

6.3.1. Key Growth Factors And Opportunities

6.3.2. Market Size And Forecast, By Country

6.3.3. Market Size And Forecast, By Indication

6.3.4. Market Size And Forecast, By End User

6.3.5. Germany

 

6.3.5.1. Germany Market Size And Forecast, By Indication

6.3.5.2. Germany Market Size And Forecast, By End User

 

6.3.6. France

 

6.3.6.1. France Market Size And Forecast, By Indication

6.3.6.2. France Market Size And Forecast, By End User

 

6.3.7. Uk

 

6.3.7.1. Uk Market Size And Forecast, By Indication

6.3.7.2. Uk Market Size And Forecast, By End User

 

6.3.8. Italy

 

6.3.8.1. Italy Market Size And Forecast, By Indication

6.3.8.2. Italy Market Size And Forecast, By End User

 

6.3.9. Rest of Europe

 

6.3.9.1. Rest of Europe Market Size And Forecast, By Indication

6.3.9.2. Rest of Europe Market Size And Forecast, By End User

 

6.4. Asia-Pacific

 

6.4.1. Key Growth Factors And Opportunities.

6.4.2. Market Size And Forecast, By Country

6.4.3. Market Size And Forecast, By Indication

6.4.4. Market Size And Forecast, By End User

6.4.5. Japan

 

6.4.5.1. Japan Market Size And Forecast, By Indication

6.4.5.2. Japan Market Size And Forecast, By End User

 

6.4.6. China

 

6.4.6.1. China Market Size And Forecast, By Indication

6.4.6.2. China Market Size And Forecast, By End User

 

6.4.7. India

 

6.4.7.1. India Market Size And Forecast, By Indication

6.4.7.2. India Market Size And Forecast, By End User

 

6.4.8. Rest of Asia-Pacific

 

6.4.8.1. Rest of Asia-Pacific Market Size And Forecast, By Indication

6.4.8.2. Rest of Asia-Pacific Market Size And Forecast, By End User

 

6.5. Lamea

 

6.5.1. Key Growth Factors And Opportunities

6.5.2. Market Size And Forecast, By Country

6.5.3. Market Size And Forecast, By Indication

6.5.4. Market Size And Forecast, By End User

6.5.5. Brazil

 

6.5.5.1. Brazil Market Size And Forecast, By Indication

6.5.5.2. Brazil Market Size And Forecast, By End User

 

6.5.6. Saudi Arabia

 

6.5.6.1. Saudi Arabia Market Size And Forecast, By Indication

6.5.6.2. Saudi Arabia Market Size And Forecast, By End User

 

6.5.7. South Africa

 

6.5.7.1. South Africa Market Size And Forecast, By Indication

6.5.7.2. South Africa Market Size And Forecast, By End User

 

6.5.8. Rest of Lamea

 

6.5.8.1. Rest of Lamea Market Size And Forecast, By Indication

6.5.8.2. Rest of Lamea Market Size And Forecast, By End User

 

Chapter 7: Company Profiles

 

7.1. Akorn Inc.

 

7.1.1. Company Overview

7.1.2. Company Snapshot

7.1.3. Operating Business Segments

7.1.4. Product Portfolio

7.1.5. Business Performance

 

7.2. Aurobindo Pharma Limited

 

7.2.1. Company Overview

7.2.2. Company Snapshot

7.2.3. Operating Business Segments

7.2.4. Product Portfolio

7.2.5. Business Performance

 

7.3. Bayer Ag

 

7.3.1. Company Overview

7.3.2. Company Snapshot

7.3.3. Operating Business Segments

7.3.4. Product Portfolio

7.3.5. Business Performance

 

7.4. Ferring Holding Sa

 

7.4.1. Company Overview

7.4.2. Company Snapshot

7.4.3. Operating Business Segments

7.4.4. Product Portfolio

7.4.5. Business Performance

 

7.5. Mylan N.V.

 

7.5.1. Company Overview

7.5.2. Company Snapshot

7.5.3. Operating Business Segments

7.5.4. Product Portfolio

7.5.5. Business Performance

 

7.6. Novartis International Ag (Sandoz)

 

7.6.1. Company Overview

7.6.2. Company Snapshot

7.6.3. Operating Business Segments

7.6.4. Product Portfolio

7.6.5. Business Performance

 

7.7. Pfizer Inc.

 

7.7.1. Company Overview

7.7.2. Company Snapshot

7.7.3. Operating Business Segments

7.7.4. Product Portfolio

7.7.5. Business Performance

 

7.8. Sanofi S.A.

 

7.8.1. Company Overview

7.8.2. Company Snapshot

7.8.3. Operating Business Segments

7.8.4. Product Portfolio

7.8.5. Business Performance

 

7.9. Takeda Pharmaceutical Company Limited

 

7.9.1. Company Overview

7.9.2. Company Snapshot

7.9.3. Operating Business Segments

7.9.4. Product Portfolio

7.9.5. Business Performance

 

7.10. Vitruvias Therapeutics Inc.

 

7.10.1. Company Overview

7.10.2. Company Snapshot

7.10.3. Operating Business Segments

7.10.4. Product Portfolio

7.10.5. Business Performance

7.10.1. Key Strategic Moves And Developments


List Of Figure

List of Figures

 

Figure 01. Antifibrinolytic Drugs, Market Segmentation

Figure 02. Top Investment Pockets

Figure 03. Top Player Positioning

Figure 04. Drivers, Restraint, And Opportunity, Antifibrinolytic Drugs Market

Figure 05. Comparative Share Analysis of Antifibrinolytic Drugs Market For Gynecology, By Country, 2018 & 2026 (%)

Figure 06. Comparative Share Analysis of Antifibrinolytic Drugs Market For Hereditary Angioedema Market, By Country, 2018 & 2026 (%)

Figure 07. Comparative Share Analysis of Antifibrinolytic Drugs Market For Fibrinolytic Response Testing, By Country, 2018 & 2026 (%)

Figure 08. Comparative Share Analysis of Antifibrinolytic Drugs Market For Surgeries, By Country, 2018 & 2026 (%)

Figure 09. Comparative Share Analysis of Antifibrinolytic Drugs Market For Others, By Country, 2018 & 2026 (%)

Figure 10. Comparative Share Analysis of Antifibrinolytic Drugs Market For Hospitals, By Country, 2018 & 2026 (%)

Figure 11. Comparative Share Analysis of Antifibrinolytic Drugs Market For Ambulatory Surgery Centers, By Country, 2018 & 2026 (%)

Figure 12. Comparative Share Analysis of Antifibrinolytic Drugs Market, For Trauma Centers By Country, 2018 & 2026 (%)

Figure 13. Akorn: Net Sales, 2016-2018 (USD Million)

Figure 14. Akorn: Revenue Share By Segment, 2018 (%)

Figure 15. Aurobindo: Net Sales, 2016-2018 (USD Million)

Figure 16. Aurobindo: Revenue Share By Segment, 2018 (%)

Figure 17. Aurobindo: Revenue Share By Region, 2018 (%)

Figure 18. Bayer: Revenue, 2016-2018 (USD Million)

Figure 19. Bayer: Revenue Share By Segment, 2018 (%)

Figure 20. Bayer: Revenue Share By Region, 2018 (%)

Figure 21. Mylan: Net Sales, 2016-2018 (USD Million)

Figure 22. Mylan: Revenue Share By Geography, 2018 (%)

Figure 23. Novartis: Net Sales, 2016-2018 (USD Million)

Figure 24. Novartis: Revenue Share By Segment, 2018 (%)

Figure 25. Novartis: Revenue Share By Geography, 2018 (%)

Figure 26. Pfizer: Revenue, 2016-2018 (USD Million)

Figure 27. Pfizer: Revenue Share By Segment, 2018 (%)

Figure 28. Pfizer: Revenue Share By Region, 2018 (%)

Figure 29. Sanofi: Net Sales, 2016-2018 (USD Million)

Figure 30. Sanofi: Revenue Share By Segment, 2018 (%)

Figure 31. Sanofi: Revenue Share By Region, 2018 (%)

Figure 32. Takeda: Net Sales, 2016-2018 (USD Million)

Figure 33. Takeda: Revenue Share By Segment, 2018 (%)

Figure 34. Takeda: Revenue Share By Region, 2018 (%)


List Of Table

List of Tables

 

Table 01. Antifibrinolytic Drugs Market, By Indication, 2018-2026 (USD Million)

Table 02. Antifibrinolytic Drugs Market For Gynecology Market, By Region, 2018-2026 (USD Million)

Table 03. Antifibrinolytic Drugs Market For Hereditary Angioedema, By Region, 2018-2026 (USD Million)

Table 04. Antifibrinolytic Drugs Market For Fibrinolytic Response Testing, By Region, 2018-2026 (USD Million)

Table 05. Antifibrinolytic Drugs Market For Surgeries, By Region, 2018-2026 (USD Million)

Table 06. Antifibrinolytic Drugs Market For Others, By Region, 2018-2026 (USD Million)

Table 07. Antifibrinolytic Drugs Market, By End User, 2018-2026 (USD Million)

Table 08. Antifibrinolytic Drugs Market For Hospitals, By Region, 2018-2026 (USD Million)

Table 09. Antifibrinolytic Drugs Corticosteroids Market For Ambulatory Surgery Centers, By Region, 2018-2026 (USD Million)

Table 10. Antifibrinolytic Drugs Market For Trauma Centers, By Region, 2018-2026 (USD Million)

Table 11. Antifibrinolytic Drugs Market, By Region, 2018-2026 (USD Million)

Table 12. North America Antifibrinolytic Drugs Market, By Country, 2018-2026 (USD Million)

Table 13. North America Antifibrinolytic Drugs Market, By Indication, 2018-2026 (USD Million)

Table 14. North America Antifibrinolytic Drugs Market, By End User, 2018-2026 (USD Million),

Table 15. U.S. Antifibrinolytic Drugs Market By Idication, 2018-2026 (USD Million)

Table 16. U.S. Antifibrinolytic Drugs Market By End User, 2018-2026 (USD Million)

Table 17. Canada Antifibrinolytic Drugs Market By Idication, 2018-2026 (USD Million)

Table 18. Canada Antifibrinolytic Drugs Market By End User, 2018-2026 (USD Million)

Table 19. Mexico Antifibrinolytic Drugs Market By Idication, 2018-2026 (USD Million)

Table 20. Mexico Antifibrinolytic Drugs Market By End User, 2018-2026 (USD Million)

Table 21. Europe Antifibrinolytic Drugs Market, By Country, 2018-2026 (USD Million)

Table 22. Europe Antifibrinolytic Drugs Market, By Indication, 2018-2026 (USD Million)

Table 23. Europe Antifibrinolytic Drugs Market, By End User, 2018-2026 (USD Million),

Table 24. Germany Antifibrinolytic Drugs Market By Indication, 2018-2026 (USD Million)

Table 25. Germany Antifibrinolytic Drugs Market By End User, 2018-2026 (USD Million)

Table 26. France Antifibrinolytic Drugs Market By Idication, 2018-2026 (USD Million)

Table 27. France Antifibrinolytic Drugs Market By End User, 2018-2026 (USD Million)

Table 28. Uk Antifibrinolytic Drugs Market By Idication, 2018-2026 (USD Million)

Table 29. Uk Antifibrinolytic Drugs Market By End User, 2018-2026 (USD Million)

Table 30. Italy Antifibrinolytic Drugs Market By Idication, 2018-2026 (USD Million)

Table 31. Italy Antifibrinolytic Drugs Market By End User, 2018-2026 (USD Million)

Table 32. Rest of Europe Antifibrinolytic Drugs Market By Idication, 2018-2026 (USD Million)

Table 33. Rest of Europe Antifibrinolytic Drugs Market By End User, 2018-2026 (USD Million)

Table 34. Asia-Pacific Antifibrinolytic Drugs Market, By Country, 2018-2026 (USD Million)

Table 35. Asia-Pacific Antifibrinolytic Drugs Market, By Indication, 2018-2026 (USD Million)

Table 36. Asia-Pacific Antifibrinolytic Drugs Market, By End User, 2018-2026 (USD Million),

Table 37. Japan Antifibrinolytic Drugs Market By Idication, 2018-2026 (USD Million)

Table 38. Japan Antifibrinolytic Drugs Market By End User, 2018-2026 (USD Million)

Table 39. China Antifibrinolytic Drugs Market By Idication, 2018-2026 (USD Million)

Table 40. China Antifibrinolytic Drugs Market By End User, 2018-2026 (USD Million)

Table 41. India Antifibrinolytic Drugs Market By Idication, 2018-2026 (USD Million)

Table 42. India Antifibrinolytic Drugs Market By End User, 2018-2026 (USD Million)

Table 43. Rest of Asia- Pacific Antifibrinolytic Drugs Market By Idication, 2018-2026 (USD Million)

Table 44. Rest of Asia- Pacific Antifibrinolytic Drugs Market By End User, 2018-2026 (USD Million)

Table 45. Lamea Antifibrinolytic Drugs Market, By Country, 2018-2026 (USD Million)

Table 46. Lamea Antifibrinolytic Drugs Market, By Indication, 2018-2026 (USD Million)

Table 47. Lamea Antifibrinolytic Drugs Market, By End User, 2018-2026 (USD Million),

Table 48. Brazil Antifibrinolytic Drugs Market By Idication, 2018-2026 (USD Million)

Table 49. Brazil Antifibrinolytic Drugs Market By End User, 2018-2026 (USD Million)

Table 50. Saudi Arabia Antifibrinolytic Drugs Market By Idication, 2018-2026 (USD Million)

Table 51. Saudi Arabia Antifibrinolytic Drugs Market By End User, 2018-2026 (USD Million)

Table 52. South Africa Antifibrinolytic Drugs Market By Idication, 2018-2026 (USD Million)

Table 53. South Africa Antifibrinolytic Drugs Market By End User, 2018-2026 (USD Million)

Table 54. Rest of Lamea Antifibrinolytic Drugs Market By Idication, 2018-2026 (USD Million)

Table 55. Rest of Lamea Antifibrinolytic Drugs Market By End User, 2018-2026 (USD Million)

Table 56. Akorn: Company Snapshot

Table 57. Akorn: Operating Segments

Table 58. Akorn: Product Portfolio

Table 59. Aurobindo: Company Snapshot

Table 60. Aurobindo: Operating Segments

Table 61. Aurobindo: Product Portfolio

Table 62. Bayer: Company Snapshot

Table 63. Bayer: Operating Segments

Table 64. Bayer: Product Portfolio

Table 65. Ferring: Company Snapshot

Table 66. Ferring: Product Portfolio

Table 67. Mylan: Company Snapshot

Table 68. Mylan: Operating Segments

Table 69. Mylan: Product Portfolio

Table 70. Novartis Ag: Company Snapshot

Table 71. Novartis: Operating Segments

Table 72. Novartis Ag: Product Portfolio

Table 73. Pfizer: Company Snapshot

Table 74. Pfizer: Operating Segments

Table 75. Pfizer: Product Portfolio

Table 76. Sanofi: Company Snapshot

Table 77. Sanofi: Operating Segments

Table 78. Sanofi: Product Portfolio

Table 79. Takeda: Company Snapshot

Table 80. Takeda: Operating Segments

Table 81. Takeda: Product Portfolio

Table 82. Vitruvias: Company Snapshot

Table 83. Vitruvias: Product Portfolio

Licence Rights

Single-User license:

This  grants one non-exclusive, non-transferable machine-readable license for the report either electronically or online. The right to store, display, use, or stockpile the report is restricted to only ONE authorized computer. For obtaining a single user license, ONLY an individual ("you") for individual use is entitled for using the product or as mentioned in the License Terms. Any individual representing an organization is refrained from accessing the products/services of AMR or as stated in the License Terms; any breach of which shall lead to violation of applicable laws in the United States, India, or in the jurisdiction of purchase. The products and services offered are the intellectual property of AMR, and are protected by applicable copyright laws, international treaty provisions, and other applicable laws of the country in which these are being used. Albeit the abovementioned, you are NOT be permitted to:

transmit or permit any third party to use and/or gain access to the report;

resell, sub-license, rent, lease, transfer, or attempt to assign the rights of the report (in whole or in part) to any party NOT authorized by AMR;

modify, alter, create database, broadcast, communicate, transfer, pledge, rent, reproduce, transmit, display, copy, distribute, commercially exploit, use, or store the content from the report other than for internal business purposes; expressly permitted above; and

use the report in any comportment that would breach the terms and conditions contained in these License Terms or that would violate the applicable laws in the United Sates, India, or in any other jurisdiction.

take photocopies, share with non-authorized users, and/or copy content from this publication to further distribute for commercial/noncommercial gains

share the information or content either electronically or in printed form with fellow-mates, public libraries, researchers, lecturers, college, university, foundation, government agency, corporate, non-profit organization or any other unauthorized users.

 

Five-User License:

This  grants up to Five non-exclusive, non-transferable machine-readable licenses for using the report either electronically or online. The right to store, transfer, display, use, or stockpile the report is restricted to only FIVE authorized users. An individual representing an organization or an organization shall ONLY purchase the five-user license. The authorized users can print additional duplicate printed copies of the report for distribution to the employees of his/her company (Personnel). Albeit the abovementioned, you are NOT be permitted to:

 

transmit or permit by any means to any third party (i.e. non-personnel) or unauthorized users for use and/or gain access to the report;

resell, sub-license, rent, lease, transfer, or attempt to redistribute or assign rights of the report (in whole or in part) to any party NOT authorized by AMR;

modify, alter, create database, broadcast, communicate, transfer, pledge, rent, reproduce, transmit, display, copy, distribute, commercially exploit, use, or store the content from the report other than for internal business purposes; exclusively permitted above; and

use the report in any comportment that would breach the terms and conditions contained in these License Terms or that would violate the applicable laws in the United Sates, India, or in any other jurisdiction.

take photocopies, share with non-authorized users, and/or copy content from this publication to further distribute for commercial or noncommercial gains.

share the information or content either electronically or as printed copies with fellow-mates, public libraries, researchers, lecturers, college, university, foundation, government agency, corporate, non-profit organization, or to more than 5 AUTHORIZED USERS.

 

Enterprise License:

This  grants global, non-exclusive, non-transferable machine-readable licenses for using the report either electronically or online, within the organization and/or its subsidiaries. The authorized users shall have complete right to store, display, transfer, and/or use the report ONLY within the organization or its subsidiaries. Authorized users can take unlimited printed copies of the report for distribution among its employees. Albeit the abovementioned, you shall NOT be permitted to:

transmit or permit by any means to any third party (i.e. non-personnel) for use and/or gain access to the report;

resell, sub-license, rent, lease, transfer or attempt to assign the rights in the report (in whole or in part) to any party NOT authorized by AMR;

modify, alter, create database, broadcast, communicate, transfer, pledge, rent, reproduce, transmit, display, copy, distribute, commercially exploit, use or store the content from the report other than for internal business purposes; expressly permitted above; and

use the report in any comportment that would breach the terms and conditions contained in these License Terms or that would violate the applicable laws in the United Sates, India, or in any other jurisdiction.

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies


Companies

Acic Fine Chems, Xanodyne Pharmaceuticals, Aurobindo Pharma Ltd., Akorn, Amerigen Pharms Ltd, Mylan, Pfizer (GenMed), Sanofi, Zydus Cadila, and Takeda

Company Profile

Company Profile Title

The global antifibrinolytic drugs market was valued at USD 1,3593 million in 2018 and is expected to reach USD 1,9333 million by 2026, registering a CAGR of 4.5% from 2019 to 2026. Antifibrinolytic is a type of drug that helps in the formation of blood clot. These drugs prevent the breakdown of fibrin, which is the main protein involved in blood clotting. These drugs can be used to prevent serious bleeding in patients suffering from life threatening conditions such as hemophilia, very heavy menstrual bleeding, or some types of vascular tumors. They are also widely used to prevent or control bleeding during or after surgery or after a traumatic injury. An increase in usage of these drugs has been witnessed since past few years, owing to their increased applications.
 
Rise in medical surgeries including dental and cardiac, accidental trauma, and increase in incidence of angioedema across the globe are the major factors that drive the antifibrinolytic drugs market growth. Antifibrinolytic drugs play a crucial role in the prevention of clot lysis and blood loss. Considerable surge in prevalence of bleeding disorders propels the antifibrinolytic drugs market growth. However, high cost of these drugs hamper the market growth. Furthermore, increase in research & development for developing novel innovative antifibrinolytic drugs is anticipated to create new opportunities for the market.
 
The market is segmented on the basis of indication, end-users, and region. On the basis of indication, it is classified into gynecology, hereditary angiedema, fibrinolytic response testing, surgeries, and others. By end user, it is divided into hospitals & clinics, ambulatory surgical centers, and healthcare specialty process. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
 
KEY BENEFITS FOR STAKEHOLDERS
 
The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
It offers a quantitative analysis from 2018 to 2026, which is expected to enable the stakeholders to capitalize on prevailing market opportunities.
Comprehensive analysis of all geographical regions is provided to determine the prevailing opportunities.
Key players are profiled, and their strategies are analyzed thoroughly to understand the competitive outlook of the global market.
 
KEY MARKET SEGMENTS
By Indication
Gynecology
Hereditary Angiedema
Fibrinolytic Response Testing
Surgeries
Others
By End User
Hospitals & Clinics
Ambulatory Surgical Centers
Trauma Centers
By Region
North America
o U.S.
o Canada
o Mexico
Europe
o Germany
o France
o UK
o Italy
o Rest of Europe
Asia Pacific
o Japan
o China
o India
o Rest of Asia-Pacific
LAMEA
o Brazil
o Saudi Arabia
o South Africa
o Rest of LAMEA
 
KEY PLAYERS
 
Acic Fine Chems
Xanodyne Pharmaceuticals
Aurobindo Pharma Ltd
Akorn
Mylan N.V.
Pfizer (GenMed)
Sanofi SA
Zydus Cadila
Takeda
Amerigen Pharms Ltd
 
READ MORE

Scope

Chapter 1: Introduction

 

1.1. Report Description

1.2. Key Benefits For Stakeholders

1.3. Key Market Segments

1.4. Research Methodology

 

1.4.1. Secondary Research

1.4.2. Primary Research

1.4.3. Analyst Tools And Models

 

Chapter 2: Executive Summary

 

2.1. Key Findings of The Study

2.2. Cxo Perspective

 

Chapter 3: Market Overview

 

3.1. Market Definition And Scope

3.2. Key Findings

 

3.2.1. Top Investment Pockets

 

3.3. Porter'S Five Forces Analysis

 

3.3.1. Moderate Bargaining Power of Buyers

3.3.2. Low Bargaining Power of Suppliers

3.3.3. Moderate Threat of Substitutes

3.3.4. Low Threat of New Entrants

3.3.5. Moderate Competitive Rivalry

 

3.4. Top Player Positioning

3.5. Market Dynamics

 

3.5.1. Drivers

 

3.5.1.1. Surge In Severe Road Accidents

3.5.1.2. Significant Increase In Surgical Procedures

 

3.5.2. Restraint

 

3.5.2.1. High Cost of These Drugs

 

3.5.3. Opportunity

 

3.5.3.1. Various Growth Opportunities In Emerging Economies

 

Chapter 4: Antifibrinolytic Drugs Market, By Indication

 

4.1. Overview

 

4.1.1. Market Size And Forecast

 

4.2. Gynecology

 

4.2.1. Key Market Trends And Opportunities

4.2.2. Market Size And Forecast

4.2.3. Market Share Analysis, By Country

 

4.3. Hereditary Angioedema

 

4.3.1. Key Market Trends And Growth Opportunities

4.3.2. Market Size And Forecast

4.3.3. Market Share Analysis, By Country

 

4.4. Fibrinolytic Response Testing

 

4.4.1. Key Market Trends And Opportunities

4.4.2. Market Size And Forecast

4.4.3. Market Share Analysis, By Country

 

4.5. Surgeries

 

4.5.1. Key Market Trends And Opportunities

4.5.2. Market Size And Forecast

4.5.3. Market Share Analysis, By Country

 

4.6. Others

 

4.6.1. Key Market Trends And Opportunities

4.6.2. Market Size And Forecast

4.6.3. Market Share Analysis, By Country

 

Chapter 5: Antifibrinolytic Drugs Market, By End User

 

5.1. Overview

 

5.1.1. Market Size And Forecast

 

5.2. Hospitals

 

5.2.1. Market Size And Forecast

5.2.2. Market Share Analysis, By Country

 

5.3. Ambulatory Surgery Centers

 

5.3.1. Market Size And Forecast

5.3.2. Market Share Analysis, By Country

 

5.4. Trauma Centers

 

5.4.1. Market Size And Forecast

5.4.2. Market Share Analysis, By Country

 

Chapter 6: Antifibrinolytic Drugs Market, By Region

 

6.1. Overview

 

6.1.1. Market Size And Forecast

 

6.2. North America

 

6.2.1. Key Market Trends And Opportunities

6.2.2. Market Size And Forecast, By Country

6.2.3. Market Size And Forecast, By Indication

6.2.4. Market Size And Forecast, By End User

6.2.5. U.S.

 

6.2.5.1. U.S. Market Size And Forecast, By Indication

6.2.5.2. U.S. Market Size And Forecast, By End User

 

6.2.6. Canada

 

6.2.6.1. Canada Market Size And Forecast, By Indication

6.2.6.2. Canada Market Size And Forecast, By End User

 

6.2.7. Mexico

 

6.2.7.1. Mexico Market Size And Forecast, By Indication

6.2.7.2. Mexico Market Size And Forecast, By End User

 

6.3. Europe

 

6.3.1. Key Growth Factors And Opportunities

6.3.2. Market Size And Forecast, By Country

6.3.3. Market Size And Forecast, By Indication

6.3.4. Market Size And Forecast, By End User

6.3.5. Germany

 

6.3.5.1. Germany Market Size And Forecast, By Indication

6.3.5.2. Germany Market Size And Forecast, By End User

 

6.3.6. France

 

6.3.6.1. France Market Size And Forecast, By Indication

6.3.6.2. France Market Size And Forecast, By End User

 

6.3.7. Uk

 

6.3.7.1. Uk Market Size And Forecast, By Indication

6.3.7.2. Uk Market Size And Forecast, By End User

 

6.3.8. Italy

 

6.3.8.1. Italy Market Size And Forecast, By Indication

6.3.8.2. Italy Market Size And Forecast, By End User

 

6.3.9. Rest of Europe

 

6.3.9.1. Rest of Europe Market Size And Forecast, By Indication

6.3.9.2. Rest of Europe Market Size And Forecast, By End User

 

6.4. Asia-Pacific

 

6.4.1. Key Growth Factors And Opportunities.

6.4.2. Market Size And Forecast, By Country

6.4.3. Market Size And Forecast, By Indication

6.4.4. Market Size And Forecast, By End User

6.4.5. Japan

 

6.4.5.1. Japan Market Size And Forecast, By Indication

6.4.5.2. Japan Market Size And Forecast, By End User

 

6.4.6. China

 

6.4.6.1. China Market Size And Forecast, By Indication

6.4.6.2. China Market Size And Forecast, By End User

 

6.4.7. India

 

6.4.7.1. India Market Size And Forecast, By Indication

6.4.7.2. India Market Size And Forecast, By End User

 

6.4.8. Rest of Asia-Pacific

 

6.4.8.1. Rest of Asia-Pacific Market Size And Forecast, By Indication

6.4.8.2. Rest of Asia-Pacific Market Size And Forecast, By End User

 

6.5. Lamea

 

6.5.1. Key Growth Factors And Opportunities

6.5.2. Market Size And Forecast, By Country

6.5.3. Market Size And Forecast, By Indication

6.5.4. Market Size And Forecast, By End User

6.5.5. Brazil

 

6.5.5.1. Brazil Market Size And Forecast, By Indication

6.5.5.2. Brazil Market Size And Forecast, By End User

 

6.5.6. Saudi Arabia

 

6.5.6.1. Saudi Arabia Market Size And Forecast, By Indication

6.5.6.2. Saudi Arabia Market Size And Forecast, By End User

 

6.5.7. South Africa

 

6.5.7.1. South Africa Market Size And Forecast, By Indication

6.5.7.2. South Africa Market Size And Forecast, By End User

 

6.5.8. Rest of Lamea

 

6.5.8.1. Rest of Lamea Market Size And Forecast, By Indication

6.5.8.2. Rest of Lamea Market Size And Forecast, By End User

 

Chapter 7: Company Profiles

 

7.1. Akorn Inc.

 

7.1.1. Company Overview

7.1.2. Company Snapshot

7.1.3. Operating Business Segments

7.1.4. Product Portfolio

7.1.5. Business Performance

 

7.2. Aurobindo Pharma Limited

 

7.2.1. Company Overview

7.2.2. Company Snapshot

7.2.3. Operating Business Segments

7.2.4. Product Portfolio

7.2.5. Business Performance

 

7.3. Bayer Ag

 

7.3.1. Company Overview

7.3.2. Company Snapshot

7.3.3. Operating Business Segments

7.3.4. Product Portfolio

7.3.5. Business Performance

 

7.4. Ferring Holding Sa

 

7.4.1. Company Overview

7.4.2. Company Snapshot

7.4.3. Operating Business Segments

7.4.4. Product Portfolio

7.4.5. Business Performance

 

7.5. Mylan N.V.

 

7.5.1. Company Overview

7.5.2. Company Snapshot

7.5.3. Operating Business Segments

7.5.4. Product Portfolio

7.5.5. Business Performance

 

7.6. Novartis International Ag (Sandoz)

 

7.6.1. Company Overview

7.6.2. Company Snapshot

7.6.3. Operating Business Segments

7.6.4. Product Portfolio

7.6.5. Business Performance

 

7.7. Pfizer Inc.

 

7.7.1. Company Overview

7.7.2. Company Snapshot

7.7.3. Operating Business Segments

7.7.4. Product Portfolio

7.7.5. Business Performance

 

7.8. Sanofi S.A.

 

7.8.1. Company Overview

7.8.2. Company Snapshot

7.8.3. Operating Business Segments

7.8.4. Product Portfolio

7.8.5. Business Performance

 

7.9. Takeda Pharmaceutical Company Limited

 

7.9.1. Company Overview

7.9.2. Company Snapshot

7.9.3. Operating Business Segments

7.9.4. Product Portfolio

7.9.5. Business Performance

 

7.10. Vitruvias Therapeutics Inc.

 

7.10.1. Company Overview

7.10.2. Company Snapshot

7.10.3. Operating Business Segments

7.10.4. Product Portfolio

7.10.5. Business Performance

7.10.1. Key Strategic Moves And Developments


List Of Figure

List of Figures

 

Figure 01. Antifibrinolytic Drugs, Market Segmentation

Figure 02. Top Investment Pockets

Figure 03. Top Player Positioning

Figure 04. Drivers, Restraint, And Opportunity, Antifibrinolytic Drugs Market

Figure 05. Comparative Share Analysis of Antifibrinolytic Drugs Market For Gynecology, By Country, 2018 & 2026 (%)

Figure 06. Comparative Share Analysis of Antifibrinolytic Drugs Market For Hereditary Angioedema Market, By Country, 2018 & 2026 (%)

Figure 07. Comparative Share Analysis of Antifibrinolytic Drugs Market For Fibrinolytic Response Testing, By Country, 2018 & 2026 (%)

Figure 08. Comparative Share Analysis of Antifibrinolytic Drugs Market For Surgeries, By Country, 2018 & 2026 (%)

Figure 09. Comparative Share Analysis of Antifibrinolytic Drugs Market For Others, By Country, 2018 & 2026 (%)

Figure 10. Comparative Share Analysis of Antifibrinolytic Drugs Market For Hospitals, By Country, 2018 & 2026 (%)

Figure 11. Comparative Share Analysis of Antifibrinolytic Drugs Market For Ambulatory Surgery Centers, By Country, 2018 & 2026 (%)

Figure 12. Comparative Share Analysis of Antifibrinolytic Drugs Market, For Trauma Centers By Country, 2018 & 2026 (%)

Figure 13. Akorn: Net Sales, 2016-2018 (USD Million)

Figure 14. Akorn: Revenue Share By Segment, 2018 (%)

Figure 15. Aurobindo: Net Sales, 2016-2018 (USD Million)

Figure 16. Aurobindo: Revenue Share By Segment, 2018 (%)

Figure 17. Aurobindo: Revenue Share By Region, 2018 (%)

Figure 18. Bayer: Revenue, 2016-2018 (USD Million)

Figure 19. Bayer: Revenue Share By Segment, 2018 (%)

Figure 20. Bayer: Revenue Share By Region, 2018 (%)

Figure 21. Mylan: Net Sales, 2016-2018 (USD Million)

Figure 22. Mylan: Revenue Share By Geography, 2018 (%)

Figure 23. Novartis: Net Sales, 2016-2018 (USD Million)

Figure 24. Novartis: Revenue Share By Segment, 2018 (%)

Figure 25. Novartis: Revenue Share By Geography, 2018 (%)

Figure 26. Pfizer: Revenue, 2016-2018 (USD Million)

Figure 27. Pfizer: Revenue Share By Segment, 2018 (%)

Figure 28. Pfizer: Revenue Share By Region, 2018 (%)

Figure 29. Sanofi: Net Sales, 2016-2018 (USD Million)

Figure 30. Sanofi: Revenue Share By Segment, 2018 (%)

Figure 31. Sanofi: Revenue Share By Region, 2018 (%)

Figure 32. Takeda: Net Sales, 2016-2018 (USD Million)

Figure 33. Takeda: Revenue Share By Segment, 2018 (%)

Figure 34. Takeda: Revenue Share By Region, 2018 (%)


List Of Table

List of Tables

 

Table 01. Antifibrinolytic Drugs Market, By Indication, 2018-2026 (USD Million)

Table 02. Antifibrinolytic Drugs Market For Gynecology Market, By Region, 2018-2026 (USD Million)

Table 03. Antifibrinolytic Drugs Market For Hereditary Angioedema, By Region, 2018-2026 (USD Million)

Table 04. Antifibrinolytic Drugs Market For Fibrinolytic Response Testing, By Region, 2018-2026 (USD Million)

Table 05. Antifibrinolytic Drugs Market For Surgeries, By Region, 2018-2026 (USD Million)

Table 06. Antifibrinolytic Drugs Market For Others, By Region, 2018-2026 (USD Million)

Table 07. Antifibrinolytic Drugs Market, By End User, 2018-2026 (USD Million)

Table 08. Antifibrinolytic Drugs Market For Hospitals, By Region, 2018-2026 (USD Million)

Table 09. Antifibrinolytic Drugs Corticosteroids Market For Ambulatory Surgery Centers, By Region, 2018-2026 (USD Million)

Table 10. Antifibrinolytic Drugs Market For Trauma Centers, By Region, 2018-2026 (USD Million)

Table 11. Antifibrinolytic Drugs Market, By Region, 2018-2026 (USD Million)

Table 12. North America Antifibrinolytic Drugs Market, By Country, 2018-2026 (USD Million)

Table 13. North America Antifibrinolytic Drugs Market, By Indication, 2018-2026 (USD Million)

Table 14. North America Antifibrinolytic Drugs Market, By End User, 2018-2026 (USD Million),

Table 15. U.S. Antifibrinolytic Drugs Market By Idication, 2018-2026 (USD Million)

Table 16. U.S. Antifibrinolytic Drugs Market By End User, 2018-2026 (USD Million)

Table 17. Canada Antifibrinolytic Drugs Market By Idication, 2018-2026 (USD Million)

Table 18. Canada Antifibrinolytic Drugs Market By End User, 2018-2026 (USD Million)

Table 19. Mexico Antifibrinolytic Drugs Market By Idication, 2018-2026 (USD Million)

Table 20. Mexico Antifibrinolytic Drugs Market By End User, 2018-2026 (USD Million)

Table 21. Europe Antifibrinolytic Drugs Market, By Country, 2018-2026 (USD Million)

Table 22. Europe Antifibrinolytic Drugs Market, By Indication, 2018-2026 (USD Million)

Table 23. Europe Antifibrinolytic Drugs Market, By End User, 2018-2026 (USD Million),

Table 24. Germany Antifibrinolytic Drugs Market By Indication, 2018-2026 (USD Million)

Table 25. Germany Antifibrinolytic Drugs Market By End User, 2018-2026 (USD Million)

Table 26. France Antifibrinolytic Drugs Market By Idication, 2018-2026 (USD Million)

Table 27. France Antifibrinolytic Drugs Market By End User, 2018-2026 (USD Million)

Table 28. Uk Antifibrinolytic Drugs Market By Idication, 2018-2026 (USD Million)

Table 29. Uk Antifibrinolytic Drugs Market By End User, 2018-2026 (USD Million)

Table 30. Italy Antifibrinolytic Drugs Market By Idication, 2018-2026 (USD Million)

Table 31. Italy Antifibrinolytic Drugs Market By End User, 2018-2026 (USD Million)

Table 32. Rest of Europe Antifibrinolytic Drugs Market By Idication, 2018-2026 (USD Million)

Table 33. Rest of Europe Antifibrinolytic Drugs Market By End User, 2018-2026 (USD Million)

Table 34. Asia-Pacific Antifibrinolytic Drugs Market, By Country, 2018-2026 (USD Million)

Table 35. Asia-Pacific Antifibrinolytic Drugs Market, By Indication, 2018-2026 (USD Million)

Table 36. Asia-Pacific Antifibrinolytic Drugs Market, By End User, 2018-2026 (USD Million),

Table 37. Japan Antifibrinolytic Drugs Market By Idication, 2018-2026 (USD Million)

Table 38. Japan Antifibrinolytic Drugs Market By End User, 2018-2026 (USD Million)

Table 39. China Antifibrinolytic Drugs Market By Idication, 2018-2026 (USD Million)

Table 40. China Antifibrinolytic Drugs Market By End User, 2018-2026 (USD Million)

Table 41. India Antifibrinolytic Drugs Market By Idication, 2018-2026 (USD Million)

Table 42. India Antifibrinolytic Drugs Market By End User, 2018-2026 (USD Million)

Table 43. Rest of Asia- Pacific Antifibrinolytic Drugs Market By Idication, 2018-2026 (USD Million)

Table 44. Rest of Asia- Pacific Antifibrinolytic Drugs Market By End User, 2018-2026 (USD Million)

Table 45. Lamea Antifibrinolytic Drugs Market, By Country, 2018-2026 (USD Million)

Table 46. Lamea Antifibrinolytic Drugs Market, By Indication, 2018-2026 (USD Million)

Table 47. Lamea Antifibrinolytic Drugs Market, By End User, 2018-2026 (USD Million),

Table 48. Brazil Antifibrinolytic Drugs Market By Idication, 2018-2026 (USD Million)

Table 49. Brazil Antifibrinolytic Drugs Market By End User, 2018-2026 (USD Million)

Table 50. Saudi Arabia Antifibrinolytic Drugs Market By Idication, 2018-2026 (USD Million)

Table 51. Saudi Arabia Antifibrinolytic Drugs Market By End User, 2018-2026 (USD Million)

Table 52. South Africa Antifibrinolytic Drugs Market By Idication, 2018-2026 (USD Million)

Table 53. South Africa Antifibrinolytic Drugs Market By End User, 2018-2026 (USD Million)

Table 54. Rest of Lamea Antifibrinolytic Drugs Market By Idication, 2018-2026 (USD Million)

Table 55. Rest of Lamea Antifibrinolytic Drugs Market By End User, 2018-2026 (USD Million)

Table 56. Akorn: Company Snapshot

Table 57. Akorn: Operating Segments

Table 58. Akorn: Product Portfolio

Table 59. Aurobindo: Company Snapshot

Table 60. Aurobindo: Operating Segments

Table 61. Aurobindo: Product Portfolio

Table 62. Bayer: Company Snapshot

Table 63. Bayer: Operating Segments

Table 64. Bayer: Product Portfolio

Table 65. Ferring: Company Snapshot

Table 66. Ferring: Product Portfolio

Table 67. Mylan: Company Snapshot

Table 68. Mylan: Operating Segments

Table 69. Mylan: Product Portfolio

Table 70. Novartis Ag: Company Snapshot

Table 71. Novartis: Operating Segments

Table 72. Novartis Ag: Product Portfolio

Table 73. Pfizer: Company Snapshot

Table 74. Pfizer: Operating Segments

Table 75. Pfizer: Product Portfolio

Table 76. Sanofi: Company Snapshot

Table 77. Sanofi: Operating Segments

Table 78. Sanofi: Product Portfolio

Table 79. Takeda: Company Snapshot

Table 80. Takeda: Operating Segments

Table 81. Takeda: Product Portfolio

Table 82. Vitruvias: Company Snapshot

Table 83. Vitruvias: Product Portfolio

Single-User license:

This  grants one non-exclusive, non-transferable machine-readable license for the report either electronically or online. The right to store, display, use, or stockpile the report is restricted to only ONE authorized computer. For obtaining a single user license, ONLY an individual ("you") for individual use is entitled for using the product or as mentioned in the License Terms. Any individual representing an organization is refrained from accessing the products/services of AMR or as stated in the License Terms; any breach of which shall lead to violation of applicable laws in the United States, India, or in the jurisdiction of purchase. The products and services offered are the intellectual property of AMR, and are protected by applicable copyright laws, international treaty provisions, and other applicable laws of the country in which these are being used. Albeit the abovementioned, you are NOT be permitted to:

transmit or permit any third party to use and/or gain access to the report;

resell, sub-license, rent, lease, transfer, or attempt to assign the rights of the report (in whole or in part) to any party NOT authorized by AMR;

modify, alter, create database, broadcast, communicate, transfer, pledge, rent, reproduce, transmit, display, copy, distribute, commercially exploit, use, or store the content from the report other than for internal business purposes; expressly permitted above; and

use the report in any comportment that would breach the terms and conditions contained in these License Terms or that would violate the applicable laws in the United Sates, India, or in any other jurisdiction.

take photocopies, share with non-authorized users, and/or copy content from this publication to further distribute for commercial/noncommercial gains

share the information or content either electronically or in printed form with fellow-mates, public libraries, researchers, lecturers, college, university, foundation, government agency, corporate, non-profit organization or any other unauthorized users.

 

Five-User License:

This  grants up to Five non-exclusive, non-transferable machine-readable licenses for using the report either electronically or online. The right to store, transfer, display, use, or stockpile the report is restricted to only FIVE authorized users. An individual representing an organization or an organization shall ONLY purchase the five-user license. The authorized users can print additional duplicate printed copies of the report for distribution to the employees of his/her company (Personnel). Albeit the abovementioned, you are NOT be permitted to:

 

transmit or permit by any means to any third party (i.e. non-personnel) or unauthorized users for use and/or gain access to the report;

resell, sub-license, rent, lease, transfer, or attempt to redistribute or assign rights of the report (in whole or in part) to any party NOT authorized by AMR;

modify, alter, create database, broadcast, communicate, transfer, pledge, rent, reproduce, transmit, display, copy, distribute, commercially exploit, use, or store the content from the report other than for internal business purposes; exclusively permitted above; and

use the report in any comportment that would breach the terms and conditions contained in these License Terms or that would violate the applicable laws in the United Sates, India, or in any other jurisdiction.

take photocopies, share with non-authorized users, and/or copy content from this publication to further distribute for commercial or noncommercial gains.

share the information or content either electronically or as printed copies with fellow-mates, public libraries, researchers, lecturers, college, university, foundation, government agency, corporate, non-profit organization, or to more than 5 AUTHORIZED USERS.

 

Enterprise License:

This  grants global, non-exclusive, non-transferable machine-readable licenses for using the report either electronically or online, within the organization and/or its subsidiaries. The authorized users shall have complete right to store, display, transfer, and/or use the report ONLY within the organization or its subsidiaries. Authorized users can take unlimited printed copies of the report for distribution among its employees. Albeit the abovementioned, you shall NOT be permitted to:

transmit or permit by any means to any third party (i.e. non-personnel) for use and/or gain access to the report;

resell, sub-license, rent, lease, transfer or attempt to assign the rights in the report (in whole or in part) to any party NOT authorized by AMR;

modify, alter, create database, broadcast, communicate, transfer, pledge, rent, reproduce, transmit, display, copy, distribute, commercially exploit, use or store the content from the report other than for internal business purposes; expressly permitted above; and

use the report in any comportment that would breach the terms and conditions contained in these License Terms or that would violate the applicable laws in the United Sates, India, or in any other jurisdiction.

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS


Companies

Acic Fine Chems, Xanodyne Pharmaceuticals, Aurobindo Pharma Ltd., Akorn, Amerigen Pharms Ltd, Mylan, Pfizer (GenMed), Sanofi, Zydus Cadila, and Takeda